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Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond VA

Results

Background
Anthracyclines are one of the most widely
studied drugs in terms of cardiotoxicity,
and are a mainstay component of anticancer regimens. Not only do one-third of
those with cancer have hypertension, but
it is also the most commonly reported
comorbidity in cancer registries. In order
to provide optimal treatment for the health
of the growing population of cancer
patients with hypertension comorbidity, it
is necessary to understand the potential
effects, if any, their hypertension and
anthracycline treatment will have on
short- and long-term cardiac function.
Figure 1

Objectives
• To assess whether anthracycline
chemotherapy exacerbates cardiotoxicity
in patients with hypertension comorbidity.

Figure 1: Diagrammatic summary of the vicious cycle for cardiovascular pathology under the
comorbidity of anthracycline cardiotoxicity and hypertension. The current and potentially promising
novel therapeutic strategies are also indicated. Abbreviations: LV – left ventricular; ACEI –
angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker.

• To describe its molecular and
pathophysiologic mechanisms
• To identify novel therapeutic modalities
to combat potential exacerbation

Methods
We performed a literature search using
the Medline database on Pubmed on all
articles addressing the relationship of
anthracycline cardiotoxicity and
hypertension.
Figure 2
Figure 2: Summary of mechanistic overlap of anthrayclines and hypertension.

Conclusion
• Von Hoff et al. reported
the earliest link between
hypertension and
doxorubicin cardiotoxicity
through a retrospective
analysis of 4018 patients
in cooperative group trials
(Von Hoff et al., 1979).
• The results of a study by
Herman et al.
demonstrate that
hypertensive rats were
more prone to cardiac
damage by doxorubicin
than the normotensive
rats (Herman et al., 1985).
• Even when compared to
hypertension comorbidity,
total cumulative dose still
remains the most
significant and major risk
factor for anthracyclinerelated CHF.
• As demonstrated in Figure
1 and Figure 2, a
pathophysiologic overlap
exists between
hypertension and
anthracycline in terms of
cardiotoxicity.

• We summarize evidence from the literature
as well as animal models that support the
claim that hypertension does indeed
worsen the cardiotoxic effects of anticancer chemotherapeutic drugs.
• Management should rest upon a careful
balance of risks and benefits. Meticulous
attention should be paid on pretreatment
screening for risk factors, robust monitoring
of cardiac function, and early intervention
for preexisting comorbidities.
• In nearly all cases, it is recommended to
first manage the patient’s hypertension
before administering anthracycline
treatment.
• Cardioprotectants (i.e. dexrazoxane)
should be explored as a viable solution on
a case-by-case basis.

Future
• As the mean age of the population
increases, and concurrently the risk of
hypertension and cancer, cardiooncologists are needed to effectively
satisfy the management of a growing
subgroup of patients.
• Further research is needed to aid in the
clinical management of these patients. For
example, little information is available on
dosing adjustments and follow-up
scheduling. Additionally, combinations of
anticancer drugs are increasingly being
used to aggressively treat various forms of
cancer. While these drugs have various
cardiac implications, it is important to
investigate the potential additive or
interactive effects of these drugs.

